Low molecular weight heparin in prevention of perioperative thrombosis - PubMed (original) (raw)
Clinical Trial
Low molecular weight heparin in prevention of perioperative thrombosis
A Leizorovicz et al. BMJ. 1992.
Abstract
Objective: To determine whether prophylactic treatment with low molecular weight heparin reduces the incidence of thrombosis in patients who have had general or orthopaedic surgery.
Design: Meta-analysis of results from 52 randomised, controlled clinical studies (29 in general surgery and 23 in orthopaedic surgery) in which low molecular weight heparin was compared with placebo, dextran, or unfractionated heparin.
Subjects: Patients who had had general or orthopaedic surgery.
Intervention: Once daily injection of a low molecular weight heparin compared with placebo, dextran, or unfractionated heparin.
Main outcome measures: Incidence of deep venous thrombosis, pulmonary embolism, major haemorrhages, and death.
Results: The results confirm that low molecular weight heparins are more efficacious for the prophylactic treatment of deep venous thrombosis than placebo (common odds ratio 0.31, 95% confidence interval 0.22 to 0.43; p < 0.001) and dextran (0.44, 0.30 to 0.65; p < 0.001). The results suggest that low molecular weight heparins are also more efficacious than unfractionated heparin (0.85, 0.74 to 0.97; p = 0.02), with no significant difference in the incidence of major haemorrhages (1.06, 0.93 to 1.20; p = 0.62).
Conclusions: Low molecular weight heparins seem to have a higher benefit to risk ratio than unfractionated heparin in preventing perioperative thrombosis. However, it remains to be shown in a suitably powered clinical trial whether low molecular weight heparin reduces the risk of fatal pulmonary embolism compared with heparin.
Comment in
- Low molecular weight heparin.
Routledge PA, West RR. Routledge PA, et al. BMJ. 1992 Oct 17;305(6859):906. doi: 10.1136/bmj.305.6859.906. BMJ. 1992. PMID: 1333862 Free PMC article. No abstract available.
Similar articles
- Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.
Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Leizorovicz A, et al. BMJ. 1994 Jul 30;309(6950):299-304. doi: 10.1136/bmj.309.6950.299. BMJ. 1994. PMID: 8086867 Free PMC article. - Prophylaxis of postoperative thromboembolism with low molecular weight heparins.
Jørgensen LN, Wille-Jørgensen P, Hauch O. Jørgensen LN, et al. Br J Surg. 1993 Jun;80(6):689-704. doi: 10.1002/bjs.1800800607. Br J Surg. 1993. PMID: 7687188 Review. - Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek MD. Leyvraz PF, et al. BMJ. 1991 Sep 7;303(6802):543-8. doi: 10.1136/bmj.303.6802.543. BMJ. 1991. PMID: 1655136 Free PMC article. Clinical Trial. - Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
[No authors listed] [No authors listed] Prescrire Int. 2013 Apr;22(137):99-101, 103-4. Prescrire Int. 2013. PMID: 23662321 Review.
Cited by
- Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, Beyer-Westendorf J. Donath L, et al. Br J Clin Pharmacol. 2012 Dec;74(6):947-58. doi: 10.1111/j.1365-2125.2012.04302.x. Br J Clin Pharmacol. 2012. PMID: 22515679 Free PMC article. - Some limits to evidence-based medicine: a case study from elective orthopaedics.
Ferlie E, Wood M, Fitzgerald L. Ferlie E, et al. Qual Health Care. 1999 Jun;8(2):99-107. doi: 10.1136/qshc.8.2.99. Qual Health Care. 1999. PMID: 10557685 Free PMC article. - Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel.
Torrente F, Meade S, Benchimol EI, de Ridder L, Croft NM, Kammermeier J, Mack DR, Klomberg RCW, Turner D, Wilson DC, Martín-de-Carpi J, Bronsky J, Amil Dias J, Walker G, van Ommen CH, Powar MP, Burgess N, Irving PM, Samaan MA, Hansen R. Torrente F, et al. J Crohns Colitis. 2022 Nov 1;16(10):1609-1616. doi: 10.1093/ecco-jcc/jjac073. J Crohns Colitis. 2022. PMID: 35608932 Free PMC article. - Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
Frampton JE, Faulds D. Frampton JE, et al. Drugs. 1994 Apr;47(4):652-76. doi: 10.2165/00003495-199447040-00007. Drugs. 1994. PMID: 7516862 Review. - Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
Dunn CJ, Sorkin EM. Dunn CJ, et al. Drugs. 1996 Aug;52(2):276-305. doi: 10.2165/00003495-199652020-00011. Drugs. 1996. PMID: 8841743 Review.
References
- Acta Chir Scand Suppl. 1990;556:42-50 - PubMed
- Thromb Haemost. 1986 Dec 15;56(3):243-6 - PubMed
- Thromb Haemost. 1991 Sep 2;66(3):368-83 - PubMed
- Thromb Res. 1990 Feb 15;57(4):577-84 - PubMed
- JAMA. 1987 Jul 17;258(3):324-5 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical